Your browser doesn't support javascript.
loading
Comparison of isolation platforms for detection of circulating renal cell carcinoma cells.
Maertens, Yvonne; Humberg, Verena; Erlmeier, Franziska; Steffens, Sandra; Steinestel, Julie; Bögemann, Martin; Schrader, Andres Jan; Bernemann, Christof.
Afiliação
  • Maertens Y; Clinic for Urology, University Hospital Muenster, Muenster, Germany.
  • Humberg V; Clinic for Urology, University Hospital Muenster, Muenster, Germany.
  • Erlmeier F; Institute for Pathology and Pathological Anatomy, Technical University Munich, Munich, Germany.
  • Steffens S; Clinic for Urology, University Hospital Muenster, Muenster, Germany.
  • Steinestel J; Clinic for Urology, University Hospital Muenster, Muenster, Germany.
  • Bögemann M; Clinic for Urology, University Hospital Muenster, Muenster, Germany.
  • Schrader AJ; Clinic for Urology, University Hospital Muenster, Muenster, Germany.
  • Bernemann C; Clinic for Urology, University Hospital Muenster, Muenster, Germany.
Oncotarget ; 8(50): 87710-87717, 2017 Oct 20.
Article em En | MEDLINE | ID: mdl-29152114
BACKGROUND: Analysis of circulating tumor cells (CTCs) has progressed in several tumor entities. However, little is known about CTCs in clear cell renal cell carcinoma (ccRCC) patients. Aim of our studies was to build a stable in vitro fundament for isolation of CTCs in ccRCC. METHODS: We compared the analytical performance of different CTC isolation methods with regard to yield and purity: EpCAM based enrichment, leukocyte depletion and size based enrichment. EpCAM and cytokeratin 8 (KRT8) as biomarker for CTCs expression were evaluated in ccRCC cell lines as well as clinical samples. RESULTS: While the EpCAM based approach failed to successfully isolate tumor cells, CD45 based approaches showed intermediate recovery rates. The cell-size based Parsortix system showed highest recovery rates. EpCAM expression was low or absent in most cell lines as well as in clinical samples, whereas KRT8 was detected as a potential biomarker in ccRCC. CONCLUSION: EpCAM based approaches might miss a high number of CTCs due to low or absent expression of EpCAM in ccRCC, as shown in cell lines as well as in patient samples. We identified the cell-sized based, label independent Parsortix system to be the most effective recovery system for ccRCC CTCs.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies Idioma: En Revista: Oncotarget Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Alemanha País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies Idioma: En Revista: Oncotarget Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Alemanha País de publicação: Estados Unidos